Potential of melatonin as a treatment option for long COVID: A call for research

Documenti analoghi

• On the use of open‐label studies for the evaluation of cannabis‐based products for the treatment of long COVID
  di: Andriy A. Gorbenko, et al.
  Pubblicazione: (2024)
• Endogenous melatonin partial metabolic clearance as a potential endogenous marker of CYP1A2 activity
  di: Akitomo Yokokawa, et al.
  Pubblicazione: (2026)
• Human hypoxia models in aerospace medicine: Potential applications for human pharmacological research
  di: Titiaan E. Post, et al.
  Pubblicazione: (2024)
• Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients
  di: Job J. Engel, et al.
  Pubblicazione: (2026)
• Methotrexate toxicity and glucarpidase: A call for dose optimization
  di: Arjen Koppen, et al.
  Pubblicazione: (2025)